Oral administration of live Shigella vaccine candidates in rhesus monkeys show no evidence of competition for colonization and immunogenicity between different serotypes

Vaccine

Volumn 32, Issue 15, 2014, Pages 1754-1760

  Ranallo, R T ^a   Kaminski, R ^a   Baqar, S ^b   Dutta, M ^a   Lugo Roman, L A ^a   Boren, T ^a   Barnoy, S ^a   Venkatesan, M M ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

Colonization; Immunogenicity; Live bivalent vaccine candidates; Rhesus monkeys; Shigella

Indexed keywords

LIVE VACCINE; SHIGELLA VACCINE; UNCLASSIFIED DRUG; WRSF 2G 12; WRSF 2G 15; WRSF2G12 VACCINE; WRSF2G15 VACCINE; WRSS 3; WRSS3 VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL EXCRETION; BLOOD ANALYSIS; EXCRETION; FECES ANALYSIS; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOBLOTTING; IMMUNOGENICITY; INTRASPECIFIC COMPETITION; MALE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RHESUS MONKEY; SEROTYPE; SHIGELLA FLEXNERI; SHIGELLA SONNEI; SHIGELLOSIS; TREATMENT RESPONSE;

COLONIZATION; IMMUNOGENICITY; LIVE BIVALENT VACCINE CANDIDATES; RHESUS MONKEYS; SHIGELLA;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL SHEDDING; FECES; IMMUNITY, HUMORAL; IMMUNITY, MUCOSAL; MACACA MULATTA; MALE; SEROTYPING; SHIGELLA FLEXNERI; SHIGELLA SONNEI; SHIGELLA VACCINES;

EID: 84895860477     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.12.068     Document Type: Article

References (24)

1. Baqar S., Bourgeois A.L., Schultheiss P.J., Walker R.I., Rollins D.M., Haberberger R.L., Pavlovskis O.R. Safety and immunogenicity of a prototype oral whole-cell killed Campylobacter vaccine administered with a mucosal adjuvant in non-human primates. Vaccine 1995, 13:22-28.
2. Barnoy S., Baqar S., Kaminski R.W., Collins T., Nemelka K., Hale T.L., Ranallo R.T., Venkatesan M.M. Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection. Vaccine 2011, 29:6371-6378.
3. Barnoy S., Jeong K.I., Helm R.F., Suvarnapunya A.E., Ranallo R.T., Tzipori S., Venkatesan M.M. Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity. Vaccine 2010, 28:1642-1654.
4. Collins T.A., Barnoy S., Baqar S., Ranallo R.T., Nemelka K.W., Venkatesan M.M. Safety and colonization of two novel VirG(IcsA)-based live Shigella sonnei vaccine strains in rhesus macaques (Macaca mulatta). Comp Med 2008, 58:88-94.
5. Coster T.S., Hoge C.W., VanDeVerg L.L., Hartman A.B., Oaks E.V., Venkatesan M.M., Cohen D., Robin G., Fontaine-Thompson A., Sansonetti P.J., Hale T.L. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun 1999, 67:3437-3443.
6. D'Hauteville H., Khan S., Maskell D.J., Kussak A., Weintraub A., Mathison J., Ulevitch R.J., Wuscher N., Parsot C., Sansonetti P.J. Two msbB genes encoding maximal acylation of lipid A are required for invasive Shigella flexneri to mediate inflammatory rupture and destruction of the intestinal epithelium. J Immunol 2002, 168:5240-5251.
7. Formal S.B., Oaks E.V., Olsen R.E., Wingfield-Eggleston M., Snoy P.J., Cogan J.P. Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei. J Infect Dis 1991, 164:533-537.
8. Hale T.L., Formal S.B. Oral shigella vaccines. Curr Top Microbiol Immunol 1989, 146:205-211.
9. Islam D., Lewis M.D., Srijan A., Bodhidatta L., Aksomboon A., Gettayacamin M., Baqar S., Scott D., Mason C.J. Establishment of a non-human primate Campylobacter disease model for the pre-clinical evaluation of Campylobacter vaccine formulations. Vaccine 2006, 24:3762-3771.
10. Jones F.R., Baqar S., Gozalo A., Nunez G., Espinoza N., Reyes S.M., Salazar M., Meza R., Porter C.K., Walz S.E. New World monkey Aotus nancymae as a model for Campylobacter jejuni infection and immunity. Infect Immun 2006, 74:790-793.
11. Kotloff K.L., Taylor D.N., Sztein M.B., Wasserman S.S., Losonsky G.A., Nataro J.P., Venkatesan M., Hartman A., Picking W.D., Katz D.E., Campbell J.D., Levine M.M., Hale T.L. Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults. Infect Immun 2002, 70:2016-2021.
12. Kotloff K.L., Winickoff J.P., Ivanoff B., Clemens J.D., Swerdlow D.L., Sansonetti P.J., Adak G.K., Levine M.M. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ 1999, 77:651-666.
13. Levine M.M., Kotloff K.L., Barry E.M., Pasetti M.F., Sztein M.B. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol 2007, 5:540-553.
14. Mel D.M., Arsic B.L., Radovanovic M.L., Litvinjenko S.A. Live oral Shigella vaccine: vaccination schedule and the effect of booster dose. Acta Microbiol Acad Sci Hung 1974, 21:109-114.
15. Oaks E.V., Hale T.L., Formal S.B. Serum immune response to Shigella protein antigens in rhesus monkeys and humans infected with Shigella spp. Infect Immun 1986, 53:57-63.
16. Orr N., Katz D.E., Atsmon J., Radu P., Yavzori M., Halperin T., Sela T., Kayouf R., Klein Z., Ambar R., Cohen D., Wolf M.K., Venkatesan M.M., Hale T.L. Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers. Infect Immun 2005, 73:8027-8032.
17. Passwell J.H., Harlev E., Ashkenazi S., Chu C., Miron D., Ramon R., Farzan N., Shiloach J., Bryla D.A., Majadly F., Roberson R., Robbins J.B., Schneerson R. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel. Infect Immun 2001, 69:1351-1357.
18. Perepelov A.V., Shekht M.E., Liu B., Shevelev S.D., Ledov V.A., Senchenkova S.N., L'Vov L.V., Shashkov A.S., Feng L., Aparin P.G., Wang L., Knirel Y.A. Shigella flexneri O-antigens revisited: final elucidation of the O-acetylation profiles and a survey of the O-antigen structure diversity. FEMS Immunol Med Microbiol 2012, 66:201-210.
19. Ranallo R.T., Barnoy S., Thakkar S., Urick T., Venkatesan M.M. Developing live Shigella vaccines using lambda Red recombineering. FEMS Immunol Med Microbiol 2006, 47:462-469.
20. Ranallo R.T., Fonseka S., Boren T.L., Bedford L.A., Kaminski R.W., Thakkar S., Venkatesan M.M. Two live attenuated Shigella flexneri 2a strains WRSf2G12 and WRSf2G15: a new combination of gene deletions for 2nd generation live attenuated vaccine candidates. Vaccine 2012, 30:5159-5171.
21. Ranallo R.T., Kaminski R.W., George T., Kordis A.A., Chen Q., Szabo K., Venkatesan M.M. Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants. Infect Immun 2009, 78:400-412.
22. Robbins J.B., Chu C., Schneerson R. Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Clin Infect Dis 1992, 15:346-361.
23. Talukder K.A., Islam Z., Islam M.A., Dutta D.K., Safa A., Ansaruzzaman M., Faruque A.S., Shahed S.N., Nair G.B., Sack D.A. Phenotypic and genotypic characterization of provisional serotype Shigella flexneri 1c and clonal relationships with 1a and 1b strains isolated in Bangladesh. J Clin Microbiol 2003, 41:110-117.
24. Talukder K.A., Mondol A.S., Islam M.A., Islam Z., Dutta D.K., Khajanchi B.K., Azmi I.J., Hossain M.A., Rahman M., Cheasty T., Cravioto A., Nair G.B., Sack D.A. A novel serovar of Shigella dysenteriae from patients with diarrhoea in Bangladesh. J Med Microbiol 2007, 56:654-658.